Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

by Johannes B. K. Schwarz, Nicolas Langwieser, Nicole N

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Radiation-induced effects on tumour cells

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

TRF2ΔBΔM induces apoptosis and senescence in the mouse liver.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Structure of different types of T-cell-engaging antibodies

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 4 The molecular configuration of the CD20 molecule

Effects of SC144 on in vivo ovarian tumor.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 2 Host immune responses, not the radiosensitivity

Figure 2S (Supplementary Data)

Stromal fibromuscular AR regulates epithelium proliferation, ECM remodelling, neovasculature formation and immune cell infiltration in Pten deficient mice.

Figure 2 Frequency and overlap of alterations

Volume 83, Issue 3, Pages (March 2013)

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 2 Effect of chromosomal instability tolerance

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Igfbp3 Modulates Cell Proliferation in the Hair Follicle

Figure 1 Overview of the imaging biomarker roadmap

Destruction of a schistosomulum (arrows) in the thoracic part of the spinal cord of a BALB/c mouse at 21 days p.i. Destruction of a schistosomulum (arrows)

Distribution of splenic T cells, B cells, and NK cells in NSG hL-7xhIL-15 humanized mice. Distribution of splenic T cells, B cells, and NK cells in NSG.

Figure 3 Determination of the primary site

Fig. 3. Enhanced EGFR signaling in Rhbdf2P159L/P159L mice.

Activation of glial cells.

The absence of host Fbln5 results in increased apoptosis and decreased proliferation in Pan02 tumors. The absence of host Fbln5 results in increased apoptosis.

Apoptosis in CAM vessels after staining with TUNEL

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Immunohistochemical staining of primary and metastatic prostatic carcinomas with anticyclin D1 and anti-Ki67 monoclonal antibodies. Immunohistochemical.

Figure 1 Gene-expression quantification methods

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Axin induces extensive apoptosis in the lymphocytes of DDTg mice.

Reduced β-catenin and cyclin D1 expression and increased apoptosis in lactating mammary gland epithelia of DDTg mice. Reduced β-catenin and cyclin D1 expression.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.211 Figure 3 Tumour-cell division coexists with apoptosis in stable tumours Figure 3 | Tumour-cell division coexists with apoptosis in stable tumours. a | Immunohistochemical assays of slides containing sequential slices of tumours from mice that remained stable after radiotherapy, stained with anti-Ki67, anti-TUNEL (scale bar: 50 μm), and anti-CD8 antibodies; Ki67, TUNEL, and CD8 are markers of cell proliferation, apoptosis, and cytotoxic T cells, respectively. Analysis of the stain patterns reveals that apoptotic cells are colocalized with CD8 T cells, whereas proliferative cells are generally located at distinct sites. b | Quantification of the relative intensity of TUNEL staining in areas of the tumour containing CD8+ and Ki67+ cells. Three or four high-power fields were counted per mouse (n = 3). **P = 0.001. Weichselbaum, R. R. et al. (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.211